Antenatal Testing for Cystic Fibrosis in Cuba, 1988-2011

被引:0
作者
Collazo, Teresa [1 ]
Lopez, Ixchel [1 ]
Clark, Yulia [1 ]
Piloto, Yaixa [1 ]
González, Laura [1 ]
Gómez, Manuel [1 ]
Garcia, Marileivis [1 ]
Reyes, Lidice [1 ]
Rodriguez, Fidel [2 ]
机构
[1] CNGM, Havana, Cuba
[2] Calixto Garcia Univ Hosp, Havana, Cuba
关键词
Cystic fibrosis; CFTR protein; molecular markers antenatal diagnosis; antenatal screening; Cuba; PRENATAL-DIAGNOSIS; CFTR GENE; MUTATION; DNA; PREVALENCE; EXPERIENCE; DISEASE;
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
INTRODUCTION Cystic fibrosis is a multisystem autosomal recessive disease with wide variability in clinical severity. It is incurable and characterized by elevated and premature mortality, as well as poor quality of life. Its frequency, lethality and devastating impact on both the physical and psychological wellbeing of patients and their families, make it a serious health problem. Its frequency in Cuba is 1 in 9862 live births, where marked molecular heterogeneity of the CFTR gene makes molecular diagnosis difficult Six mutations have been identified that together enable molecular characterization of only 55.5% of cystic fibrosis chromosomes.This paper presents national results of antenatal diagnostic testing, Using direct and indirect methods, for detection of cystic fibrosis. OBJECTIVE Characterize the Cuban public health system's experience with antenatal molecular testing for cystic fibrosis from 1988 through 2011. METHODS A retrospective descriptive study was conducted with results of antenatal diagnostic testing of amniotic fluid, performed nationwide from 1988 through 2011 for 108 fetuses of couples with some risk of having children affected by cystic fibrosis, who requested testing. Polyrnerase chain reaction detected mutations p.F508del, p.G542X, p.R1162X, p.R334W, p.R553X and c.3120+1G>A; and markers XV2C and KM19. Data were analyzed using absolute frequencies and percentages, and presented in tables. RESULTS For 93 cases (86.1%), testing for cystic fibrosis was done using direct analysis of Mutations p.F508del, p.G542X, p.R1162X, p.R334W, p.R553X and c.3120+1G>A; five cases (4.6%) were tested indirectly using markers XV2C/Taq 1 and KM19/Pst I; and 10 (9.3%) were tested using a combinationt the two methods. A total of 72 diagnoses (66.7% of studies done) were concluded, of which there were 20 healthy fetuses, 16 affected, 27 carrier, and 9 who were either healthy or carriers Of an unknown mutation. CONCLUSIONS Direct or indirect molecular study was successfully used in over half of antenatal tests requested by couples throughout Cuba at risk of having children affected by cystic fibrosis, which is of great social value because of CF's burden on affected persons and their families.
引用
收藏
页码:18 / 21
页数:4
相关论文
共 50 条
  • [1] Antenatal Cytogenetic Testing in Havana, Cuba
    Mendez-Rosado, Luis A.
    Quinones, Olga
    Molina, Odalys
    Gonzalez, Nereida
    del Sol, Marylin
    Maceiras, Luanda
    Bravo, Yomisleidy
    MEDICC REVIEW, 2014, 16 (3-4) : 27 - 34
  • [2] Willingness to pay for antenatal carrier screening for cystic fibrosis
    Donaldson, C
    Shackley, P
    Abdalla, M
    Miedzybrodzka, Z
    HEALTH ECONOMICS, 1995, 4 (06) : 439 - 452
  • [3] Pilot study of the acceptability of cystic fibrosis carrier testing during routine antenatal consultations in general practice
    Harris, H
    Scotcher, D
    Hartley, N
    Wallace, A
    Craufurd, D
    Harris, R
    BRITISH JOURNAL OF GENERAL PRACTICE, 1996, 46 (405) : 225 - 227
  • [4] Towards an improved antenatal screening for cystic fibrosis
    Serre, JL
    Feingold, J
    Simon-Bouy, B
    Muller, F
    REVUE D EPIDEMIOLOGIE ET DE SANTE PUBLIQUE, 2003, 51 (02): : 245 - 253
  • [5] Highlighting the impact of cascade carrier testing in cystic fibrosis families
    Dugueperoux, Ingrid
    L'Hostis, Carine
    Audrezet, Marie-Pierre
    Rault, Gilles
    Frachon, Irene
    Bernard, Remy
    Parent, Philippe
    Blayau, Martine
    Schmitt, Sebastien
    Genin, Emmanuelle
    Ferec, Claude
    Scotet, Virginie
    JOURNAL OF CYSTIC FIBROSIS, 2016, 15 (04) : 452 - 459
  • [6] The prevalence, clinical status and genotype of cystic fibrosis patients living in Cuba using national registry data
    Rodriguez-Cala, Fidel
    Suarez-Medina, Ramon
    Josefina Venero-Fernandez, Silvia
    Smyth, Alan
    Carr, Siobhan B.
    Fogarty, Andrew W.
    JOURNAL OF CYSTIC FIBROSIS, 2019, 18 (04) : 522 - 524
  • [7] Neurologic disorders, in-hospital deaths, and years of potential life lost in the USA, 1988-2011
    Rosenbaum, Benjamin P.
    Kelly, Michael L.
    Kshettry, Varun R.
    Weil, Robert J.
    JOURNAL OF CLINICAL NEUROSCIENCE, 2014, 21 (11) : 1874 - 1880
  • [8] Diagnostic Testing in Cystic Fibrosis
    Brewington, John
    Clancy, J. P.
    CLINICS IN CHEST MEDICINE, 2016, 37 (01) : 31 - +
  • [9] ANTENATAL DIAGNOSIS, NEONATAL SCREENING AND CARRIER DETECTION FOR CYSTIC-FIBROSIS OF PANCREAS
    FREZAL, J
    BRIARD, ML
    FARRIAUX, JP
    BLANCHER, MG
    SUREAU, MC
    PELLERIN, MD
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 1993, 177 (03): : 405 - 412
  • [10] Newborn bloodspot screening for cystic fibrosis: What do antenatal and postnatal women know about cystic fibrosis?
    Fitzgerald, C.
    Linnane, B.
    Heery, E.
    Conneally, N.
    George, S.
    Fitzpatrick, P.
    JOURNAL OF CYSTIC FIBROSIS, 2016, 15 (04) : 436 - 442